ResMed Business Model Canvas
ResMed Business Model Canvas: Innovation + Recurring Revenue—Download Editable Templates
Explore ResMed’s Business Model Canvas to see how the company combines medical device innovation, subscription-like software services, and global channel partnerships to capture recurring revenue and scale clinical outcomes.
Download the full, editable Canvas (Word & Excel) for a section-by-section breakdown—perfect for investors, strategists, and founders who want actionable insights and ready-to-use templates.
Partnerships
Strategic Healthcare Provider Alliances
ResMed partners with a global network of sleep clinics, hospitals, and specialists who drive diagnosis and prescriptions; these clinical alliances, active across 140 countries, account for roughly 65–70% of ResMed’s device sales in 2025 (company revenue mix).
Insurance and Government Payers
ResMed partners with private insurers and US government payers (Medicare/Medicaid) to secure reimbursement for CPAP devices, masks, and remote monitoring; Medicare Part B covers durable medical equipment for sleep apnea, supporting ~40% of US CPAP claims in 2024.
Favorable coverage boosts access among low-income and elderly patients, helping ResMed sustain recurring revenue—device and cloud services drove $4.8B in FY2024 sales, with recurring revenue growth of ~12% year-over-year.
Home Medical Equipment (HME) Distributors
ResMed depends on a network of ~10,000 DME/HME providers who fulfill home deliveries and account for roughly 60% of device and consumable revenue; these partners are heavy users of ResMed’s Brightree billing and AirView patient-management platforms, driving recurring SaaS uptake. As of late 2025, supplier ties support scale of the SaaS ecosystem and sustain a steady cadence of replacement masks/accessories, which represent ~25% of annual consumables sales.
Technology and Consumer Electronics Leaders
ResMed’s 2025 tie-up with Apple produced the Kontor Head Strap for Apple Vision Pro, blending ResMed facial-interface IP with spatial computing to reach consumer sleep-health users; ResMed reported device-platform collaborations drove a 12% revenue lift in digital services in FY2025 (ended Sept 30, 2025).
These partnerships feed ResMed Cloud data into Apple Health and other platforms, expanding addressable consumer market beyond clinical OSA (obstructive sleep apnea) patients to an estimated 60M US adults tracking sleep in 2024.
- 2025 Kontor Head Strap co-dev with Apple
- 12% FY2025 digital services revenue growth
- Integration with Apple Health, Fitbit APIs
- Addresses ~60M US consumer sleep trackers
Component and Logistics Suppliers
ResMed’s manufacturing stability hinges on partnerships with semiconductor firms and niche component suppliers; by 2025 ResMed reported inventory days fell to ~58 from 72 in 2022 after supplier diversification for the AirSense 11 rollout.
Efficient global logistics keep gross margins high—logistics optimization cut freight per unit ~12% in 2024, supporting distribution of heavy devices and frequent replacement parts.
- Inventory days: ~58 (2025)
- Inventory days: 72 (2022)
- Freight cost per unit reduced ~12% (2024)
- Supports AirSense 11 global rollout (2023–2025)
ResMed drives $4.8B recurring revenue via 140-country network, 10K partners, 65–70% device sales
ResMed’s key partners—140-country clinical network, ~10,000 DME/HME providers, insurers (including Medicare), semiconductor suppliers, and platform deals (Apple, Fitbit)—drive ~65–70% device sales, ~60% device+consumable fulfillment, recurring revenue of $4.8B FY2024 (+12% YoY digital services FY2025), inventory days ~58 (2025), freight/unit −12% (2024).
| Metric | Value |
|---|---|
| Clinical network reach | 140 countries |
| Device sales share | 65–70% |
| DME/HME partners | ~10,000 |
| Recurring revenue | $4.8B FY2024 |
| Digital services growth | +12% FY2025 |
| Inventory days | ~58 (2025) |
| Freight/unit change | −12% (2024) |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for ResMed detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure and revenue streams, reflecting real-world operations and strategic priorities to support investor presentations, competitive analysis, and decision-making.
Customizable Excel Spreadsheet
High-level view of ResMed’s business model as a pain-point reliever, highlighting how its device-software-service ecosystem streamlines respiratory care, reduces hospital readmissions, and accelerates patient adherence—editable for quick team alignment or board review.
Activities
Advanced Research and Development
R&D drives ResMed’s product pipeline, with the company allocating about 6.4% of 2025 revenue (≈USD 520 million on USD 8.125 billion sales) to new product development, targeting next‑gen cloud‑connected CPAPs, quieter motors, and improved mask comfort.
ResMed also scales AI/ML investments to build predictive sleep‑health algorithms, using tens of millions of anonymized nights of device data to flag risks like atrial fibrillation and COPD exacerbations.
High-Precision Manufacturing
ResMed runs high-precision plants in Singapore and Australia producing medical-grade CPAPs and masks at scale; in 2025 operational excellence and cost cuts drove gross margins above 60% and reduced manufacturing cost per unit by ~8% year-over-year.
Digital Health Software Development
ResMed dedicates a large share of R&D and ops to its digital health stack—myAir, AirView—supporting remote monitoring for ~6.5M devices and enabling clinicians to troubleshoot and adjust settings without visits, reducing in-person interventions by an estimated 18% in 2024. In 2025 software dev expanded into Residential Care Software (RCS), integrating Brightree and MEDIFOX DAN to serve ~12,000 out‑of‑hospital providers and add an estimated $150M ARR.
Global Marketing and Brand Awareness
ResMed runs large-scale campaigns to raise awareness of sleep apnea and COPD, targeting hundreds of millions undiagnosed people; in 2025 it launched the Tackle Your Sleep campaign as Official Sleep Partner of the British and Irish Lions tour to broaden reach and destigmatize therapy.
These efforts pair consumer digital screening tools, educational outreach, and marketing to drive earlier diagnosis and uptake of devices and cloud services, supporting ResMed’s 2024 revenue of US$4.9B and recurring SaaS growth.
- 2025 Tackle Your Sleep: Lions partnership
- Targets hundreds of millions undiagnosed
- Uses digital screening + education
- Aims to boost device and SaaS adoption
- Supports ResMed’s US$4.9B 2024 revenue
Clinical Data Analytics and AI Integration
ResMed analyzes over 20 billion nights of sleep data to optimize therapy outcomes and deliver provider-ready insights, driving a shift from device sales to recurring digital revenue—digital health and software subscriptions contributed about 28% of FY2025 revenue (~$1.6B of $5.7B reported through Sep 30, 2025).
The data refines AI coaching in myAir to boost adherence (studies show 10–20% adherence gains), supporting remote patient monitoring and higher lifetime customer value.
- 20+ billion nights of data
- myAir AI boosts adherence ~10–20%
- FY2025 digital revenue ~ $1.6B (28% of $5.7B)
ResMed pivots to recurring revenue: $1.6B SaaS, 6.5M cloud devices, AI boosts adherence
R&D, manufacturing, and digital services drive ResMed’s shift to recurring revenue: FY2025 sales ~$5.7B with digital/SaaS ~$1.6B (28%); R&D ~6.4% (~$520M); 6.5M devices on cloud; 20B+ nights of data; myAir AI lifts adherence 10–20%; manufacturing cost/unit down ~8%; campaigns target hundreds of millions undiagnosed.
| Metric | 2025 |
|---|---|
| Revenue | $5.7B |
| Digital/SaaS | $1.6B (28%) |
| R&D | $520M (6.4%) |
| Devices cloud | 6.5M |
| Data nights | 20B+ |
Full Document Unlocks After Purchase
Business Model Canvas
The document you're previewing is the authentic ResMed Business Model Canvas—not a mockup or sample—and reflects the exact structure and content you’ll receive after purchase.
On completion of your order you’ll get this same professional, ready-to-edit file, formatted consistently and delivered in both Word and Excel for immediate use.
No placeholders or hidden sections—what you see here is the real deliverable, ready for presentation and customization.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
ResMed Business Model Canvas: Innovation + Recurring Revenue—Download Editable Templates
Explore ResMed’s Business Model Canvas to see how the company combines medical device innovation, subscription-like software services, and global channel partnerships to capture recurring revenue and scale clinical outcomes.
Download the full, editable Canvas (Word & Excel) for a section-by-section breakdown—perfect for investors, strategists, and founders who want actionable insights and ready-to-use templates.
Partnerships
Strategic Healthcare Provider Alliances
ResMed partners with a global network of sleep clinics, hospitals, and specialists who drive diagnosis and prescriptions; these clinical alliances, active across 140 countries, account for roughly 65–70% of ResMed’s device sales in 2025 (company revenue mix).
Insurance and Government Payers
ResMed partners with private insurers and US government payers (Medicare/Medicaid) to secure reimbursement for CPAP devices, masks, and remote monitoring; Medicare Part B covers durable medical equipment for sleep apnea, supporting ~40% of US CPAP claims in 2024.
Favorable coverage boosts access among low-income and elderly patients, helping ResMed sustain recurring revenue—device and cloud services drove $4.8B in FY2024 sales, with recurring revenue growth of ~12% year-over-year.
Home Medical Equipment (HME) Distributors
ResMed depends on a network of ~10,000 DME/HME providers who fulfill home deliveries and account for roughly 60% of device and consumable revenue; these partners are heavy users of ResMed’s Brightree billing and AirView patient-management platforms, driving recurring SaaS uptake. As of late 2025, supplier ties support scale of the SaaS ecosystem and sustain a steady cadence of replacement masks/accessories, which represent ~25% of annual consumables sales.
Technology and Consumer Electronics Leaders
ResMed’s 2025 tie-up with Apple produced the Kontor Head Strap for Apple Vision Pro, blending ResMed facial-interface IP with spatial computing to reach consumer sleep-health users; ResMed reported device-platform collaborations drove a 12% revenue lift in digital services in FY2025 (ended Sept 30, 2025).
These partnerships feed ResMed Cloud data into Apple Health and other platforms, expanding addressable consumer market beyond clinical OSA (obstructive sleep apnea) patients to an estimated 60M US adults tracking sleep in 2024.
- 2025 Kontor Head Strap co-dev with Apple
- 12% FY2025 digital services revenue growth
- Integration with Apple Health, Fitbit APIs
- Addresses ~60M US consumer sleep trackers
Component and Logistics Suppliers
ResMed’s manufacturing stability hinges on partnerships with semiconductor firms and niche component suppliers; by 2025 ResMed reported inventory days fell to ~58 from 72 in 2022 after supplier diversification for the AirSense 11 rollout.
Efficient global logistics keep gross margins high—logistics optimization cut freight per unit ~12% in 2024, supporting distribution of heavy devices and frequent replacement parts.
- Inventory days: ~58 (2025)
- Inventory days: 72 (2022)
- Freight cost per unit reduced ~12% (2024)
- Supports AirSense 11 global rollout (2023–2025)
ResMed drives $4.8B recurring revenue via 140-country network, 10K partners, 65–70% device sales
ResMed’s key partners—140-country clinical network, ~10,000 DME/HME providers, insurers (including Medicare), semiconductor suppliers, and platform deals (Apple, Fitbit)—drive ~65–70% device sales, ~60% device+consumable fulfillment, recurring revenue of $4.8B FY2024 (+12% YoY digital services FY2025), inventory days ~58 (2025), freight/unit −12% (2024).
| Metric | Value |
|---|---|
| Clinical network reach | 140 countries |
| Device sales share | 65–70% |
| DME/HME partners | ~10,000 |
| Recurring revenue | $4.8B FY2024 |
| Digital services growth | +12% FY2025 |
| Inventory days | ~58 (2025) |
| Freight/unit change | −12% (2024) |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for ResMed detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure and revenue streams, reflecting real-world operations and strategic priorities to support investor presentations, competitive analysis, and decision-making.
Customizable Excel Spreadsheet
High-level view of ResMed’s business model as a pain-point reliever, highlighting how its device-software-service ecosystem streamlines respiratory care, reduces hospital readmissions, and accelerates patient adherence—editable for quick team alignment or board review.
Activities
Advanced Research and Development
R&D drives ResMed’s product pipeline, with the company allocating about 6.4% of 2025 revenue (≈USD 520 million on USD 8.125 billion sales) to new product development, targeting next‑gen cloud‑connected CPAPs, quieter motors, and improved mask comfort.
ResMed also scales AI/ML investments to build predictive sleep‑health algorithms, using tens of millions of anonymized nights of device data to flag risks like atrial fibrillation and COPD exacerbations.
High-Precision Manufacturing
ResMed runs high-precision plants in Singapore and Australia producing medical-grade CPAPs and masks at scale; in 2025 operational excellence and cost cuts drove gross margins above 60% and reduced manufacturing cost per unit by ~8% year-over-year.
Digital Health Software Development
ResMed dedicates a large share of R&D and ops to its digital health stack—myAir, AirView—supporting remote monitoring for ~6.5M devices and enabling clinicians to troubleshoot and adjust settings without visits, reducing in-person interventions by an estimated 18% in 2024. In 2025 software dev expanded into Residential Care Software (RCS), integrating Brightree and MEDIFOX DAN to serve ~12,000 out‑of‑hospital providers and add an estimated $150M ARR.
Global Marketing and Brand Awareness
ResMed runs large-scale campaigns to raise awareness of sleep apnea and COPD, targeting hundreds of millions undiagnosed people; in 2025 it launched the Tackle Your Sleep campaign as Official Sleep Partner of the British and Irish Lions tour to broaden reach and destigmatize therapy.
These efforts pair consumer digital screening tools, educational outreach, and marketing to drive earlier diagnosis and uptake of devices and cloud services, supporting ResMed’s 2024 revenue of US$4.9B and recurring SaaS growth.
- 2025 Tackle Your Sleep: Lions partnership
- Targets hundreds of millions undiagnosed
- Uses digital screening + education
- Aims to boost device and SaaS adoption
- Supports ResMed’s US$4.9B 2024 revenue
Clinical Data Analytics and AI Integration
ResMed analyzes over 20 billion nights of sleep data to optimize therapy outcomes and deliver provider-ready insights, driving a shift from device sales to recurring digital revenue—digital health and software subscriptions contributed about 28% of FY2025 revenue (~$1.6B of $5.7B reported through Sep 30, 2025).
The data refines AI coaching in myAir to boost adherence (studies show 10–20% adherence gains), supporting remote patient monitoring and higher lifetime customer value.
- 20+ billion nights of data
- myAir AI boosts adherence ~10–20%
- FY2025 digital revenue ~ $1.6B (28% of $5.7B)
ResMed pivots to recurring revenue: $1.6B SaaS, 6.5M cloud devices, AI boosts adherence
R&D, manufacturing, and digital services drive ResMed’s shift to recurring revenue: FY2025 sales ~$5.7B with digital/SaaS ~$1.6B (28%); R&D ~6.4% (~$520M); 6.5M devices on cloud; 20B+ nights of data; myAir AI lifts adherence 10–20%; manufacturing cost/unit down ~8%; campaigns target hundreds of millions undiagnosed.
| Metric | 2025 |
|---|---|
| Revenue | $5.7B |
| Digital/SaaS | $1.6B (28%) |
| R&D | $520M (6.4%) |
| Devices cloud | 6.5M |
| Data nights | 20B+ |
Full Document Unlocks After Purchase
Business Model Canvas
The document you're previewing is the authentic ResMed Business Model Canvas—not a mockup or sample—and reflects the exact structure and content you’ll receive after purchase.
On completion of your order you’ll get this same professional, ready-to-edit file, formatted consistently and delivered in both Word and Excel for immediate use.
No placeholders or hidden sections—what you see here is the real deliverable, ready for presentation and customization.
